A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Researchers at New Jersey Institute of Technology in collaboration with Ohio University and Merck & Co. Inc. recently developed a new efficient method for targeted protein analysis -- one they say could speed up processes for disease testing, drug discovery and vaccine development.
Six months into the COVID-19 pandemic, more than 7.4 million people have been infected, and more than 410 000 have died. As yet, there is no treatment or vaccine for the disease.
A tuberculosis vaccine developed 100 years ago also makes vaccinated persons less susceptible to other infections.
A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus that causes the disease, when tested in animals and human cell cultures.
A significant site of damage during COVID-19 infection is the lungs. Understanding how the lungs' immune cells are responding to viral infections could help scientists develop a vaccine.
For the first time, researchers at The Westmead Institute for Medical Research have identified and described a new and unique subset of human cells that are involved in the immune response against hepatitis B (HBV) infection. The discovery could help develop new treatments for HBV and inform future vaccine design.
A clinical case of Japanese encephalitis is diagnosed in over 68,000 individuals every year, leading to the death of one in four of these affected patients.
New research from University of Alberta microbiologists has shed new light on how the respiratory syncytial virus (RSV)--one of the most common viral infections--breaks into our cells to cause infection.
Scientists have discovered a way to transform antibody drugs into antibodies with powerful anti-cancer activity through a simple molecular "switch".
As scientists across the globe race to develop a vaccine against SARS-CoV-2, the coronavirus that causes COVID-19, an international team led by Davide Corti at Vir Biotechnology and David Veesler at the University of Washington has been working around the clock on a complementary approach - identifying neutralizing antibodies that could be used as a preventative treatment or as a post-exposure therapy.
According to researchers, patients infected with severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 generate antibodies that adhere to the other coronavirus; however, the cross-reactive antibodies are not actually cross-protective, as far as cell-culture experiments are concerned.
A molecular biologist is working with a world leader in artificial intelligence-based drug discovery to help find a molecule that could prevent SARS-CoV-2.
Globally, researchers are racing against time to design a vaccine to guard against the COVID-19 infection, and epidemiologists are taking efforts to predict the way the coronavirus pandemic will spread until the availability of such a vaccine.
Vaccines are regarded as an effective intervention to stop the spread of infectious diseases. They produce antibodies by activating the immune system.
Entos Pharmaceuticals, a healthcare biotechnology company developing next generation nucleic acid medicines with their Fusogenix delivery platform announced today a partnership with Precision NanoSystems, Inc., (PNI), a global leader in enabling transformative nanomedicines, to produce clinical grade vaccines and therapeutics using PNI's NanoAssemblr GMP System.
A majority of the recently discharged patients who have currently recovered from the COVID-19 infection create virus-specific T cells and antibodies.
The hunt for an effective treatment for COVID-19 has led one team of researchers to find an improbable ally for their work: a llama named Winter.
Scientists have discovered two specific types of cells in the nose that are believed to be the initial infection points for COVID-19 coronavirus.
A global race is underway to discover a vaccine, drug, or combination of treatments that can disrupt the SARS-CoV-2 virus, which causes the COVID-19 disease, and prevent widespread deaths.
At the University of California San Diego, nanoengineers are making efforts to develop a vaccine for COVID-19 using a plant virus—an unconventional candidate.